Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1)
Top Cited Papers
- 1 November 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 39 (11) , 3015-3021
- https://doi.org/10.1161/strokeaha.108.519942
Abstract
Background and Purpose—This randomized, double-blind, placebo-controlled, dose-finding study assessed efficacy and safety of 1, 5, and 15 mg/h intravenous clazosentan, an endothelin receptor antagonist, in preventing vasospasm after aneurysmal subarachnoid hemorrhage.Methods—Patients (n=413) were randomized to placebo or clazosentan beginning within 56 hours and continued up to 14 days after initiation of treatment. The primary end point was moderate or severe angiographic vasospasm based on centrally read, blinded evaluation of digital subtraction angiography at baseline and 7 to 11 days postsubarachnoid hemorrhage. A morbidity/mortality end point, including all-cause mortality, new cerebral infarct from any cause, delayed ischemic neurological deficit due to vasospasm, or use of rescue therapy, was evaluated by local assessment. Clinical outcome was assessed by the extended Glasgow Outcome Scale at 12 weeks.Results—Moderate or severe vasospasm was reduced in a dose-dependent fashion from 66% in the placebo group to 23% in the 15 mg/h clazosentan group (risk reduction, 65%; 95% CI, 47% to 78%;PConclusions—Clazosentan significantly decreased moderate and severe vasospasm in a dose-dependent manner and showed a trend for reduction in vasospasm-related morbidity/mortality in patients with aneurysmal subarachnoid hemorrhage when centrally assessed. Overall, the adverse effects were manageable and not considered serious.Keywords
This publication has 22 references indexed in Scilit:
- Novel Mechanism of Endothelin-1-Induced Vasospasm after Subarachnoid HemorrhageJournal of Cerebral Blood Flow & Metabolism, 2007
- Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugsJournal of Neurosurgery, 2007
- Impairment of Cerebral Perfusion and Infarct Patterns Attributable to Vasospasm After Aneurysmal Subarachnoid HemorrhageStroke, 2007
- Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: Inhibitory effect on endothelinA receptor—mediated contractionJournal of Neurosurgery, 2005
- Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 2002
- Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?International Journal of Cardiology, 2002
- Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New ZealandJournal of Neurosurgery, 1996
- Endothelin and the production of cerebral vasospasm in dogsBiochemical and Biophysical Research Communications, 1989
- Nimodipine treatment in poor-grade aneurysm patientsJournal of Neurosurgery, 1988
- Acute hydrocephalus after aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 1985